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quently had a survival advantage of clinical relevance. When tumor 
response was introduced in the Cox model (as a four level variable), the 
difference in Overall Survival between PCG and PC changed from a 
signiﬁcant level (HR=1.28; CI 1.00-1.63; P=0.049) to a not signiﬁcant 
level (HR=0.99; CI: 0.76 - 1.28; P=0.97). 
Conclusions: To our knowledge this is the ﬁrst report showing a sig-
niﬁcant direct correlation between Response and Survival in NSCLC 
according to Prentice criteria.
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Background: ACTION (Assessment of Costs and ouTcomes of 
chemotherapy In an Observational setting in patients with advanced 
NSCLC) is a prospective, pan-European observational study. The ob-
jective of ACTION is to describe advanced NSCLC treatment patterns 
and patient outcomes in routine clinical practice.
Methods: Chemonaive patients (pts) aged ≥ 18 yrs with stage IIIb/IV 
NSCLC were observed for 18 months from presentation for initiation 
of ﬁrst line chemotherapy (CT). All pt care, including CT given, was at 
the discretion of the pt/physician. Pts were excluded if participating in 
a clinical trial. Overall survival was estimated using the Kaplan Meier 
method. Assessment of prognostic factors for survival was performed 
using Cox’s proportional hazards model.
Results: 975 patients were enrolled between April 2003 and Septem-
ber 2004, with observations completed in March 2006. Median age 
was 65 yrs (32-90) with 28.3% of pts aged ≥70 yrs; 71.3% were male; 
65.2% had stage IV disease. Of 487 pts who experienced weight loss, 
172 lost >10% body weight in 4 weeks prior to the start of CT. Overall 
WHO PS at baseline was 0 (21.1%), 1 (65.1%), 2 (10.0%), 3 (3.3%), 4 
(0.5%). One-year survival rate was estimated to be 39.5%. Unadjusted 
median survival time for all pts was 9.3 months (mo) (95% CI 8.6-
10.3), for pts receiving 3rd generation CT [either gemcitabine (gem), 
vinorelbine (vino) or taxane] with a platinum compound as ﬁrst line 
CT: 9.9 mo (8.6 - 10.7), for pts receiving ﬁrst line monotherapy (either 
gem or vino): 9.7 mo (7.3-12.3) and for pts receiving any other CT: 7.9 
mo (6.4-9.3). Assessment of prognostic factors for survival resulted in 
a ﬁnal Cox proportional Hazard model including treatment, WHO PS, 
number of metastatic organs, gender and age as prognostic factors. The 
hazard ratio (HR) for pts with baseline WHO PS 1 vs. PS 0 was 1.224 
(95% HR Conﬁdence Limits 0.994 - 1.509), baseline WHO PS 2 vs. 
PS 0: HR 2.006 (1.466 - 2.745), baseline WHO PS 3/4 vs. PS 0: 2.790 
(1.799 - 4.328). The HR for pts with 1 metastatic organ at baseline vs. 
none was 0.947 (0.777 - 1.154), 2 vs. 0: 1.111 (0.866 - 1.424), 3 vs. 0: 
1.301 (0.870 - 1.944) and 4-6 vs. 0: 3.442 (2.082 - 5.592). For female 
vs. male pts the HR was 0.716 (0.592 - 0.866). The HR for baseline age 
was 0.991 (0.982 - 1.000).
Conclusion: ACTION is the ﬁrst large-scale observational study of 
pts with advanced NSCLC. Median survival is comparable to previ-
ous clinical trial results (e.g. le Chevalier et al, 2005); even though 
the prognosis for these pts indicated that a worse outcome was likely. 
Analysis of factors inﬂuencing survival also reinforce previous clinical 
trial results, as it is seen that gender, baseline WHO PS and disease 
stage signiﬁcantly impact on overall survival, as reported in Schiller et 
al (2002).
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Background: Pemetrexed exhibited comparable efﬁcacy and mild 
toxicity in a phase III trial comparing pemetrexed 500 mg/m2 with 
docetaxel 75 mg/m2 in vitamin-supplemented advanced NSCLC 
patients. A second phase III trial was initiated to determine if the peme-
trexed dose could be escalated to increase efﬁcacy, without resulting in 
an unacceptable increase in toxicity.
Methods: Patients with locally advanced or metastatic NSCLC, previ-
ously treated with platinum-based chemotherapy, were randomized to 
iv pemetrexed 500 (P500) or pemetrexed 900 mg/m2 (P900) q 3week. 
The study was terminated after 588 out of 600 patients had enrolled 
since an interim analysis indicated a low probability of a survival ad-
vantage and somewhat greater frequency of toxicity on the P900 arm. 
Patients were allowed to continue treatment at the P500 dose.
Results: Baseline characteristics of patients were balanced on both 
arms: ~67% males, median age 62 yrs, 87% pts with an ECOG PS of 
0 or 1, and 77% pts with stage IV disease. Five hundred eighty-eight 
randomized patients were evaluated for survival; 581 patients, who 
received ≥1 dose, for safety; 509 patients, who received ≥2 cycles and 
had measurable disease, for tumor response. Safety data for patients 
who switched from P900 to P500 were analyzed separately. There was 
no statistical difference between treatment arms for any efﬁcacy mea-
sure: median survival P500 6.7 mo versus P900 6.9 mo, HR=1.0132 
(95% CI 0.837, 1.226); progression-free survival P500 2.6 mo versus 
P900 2.8 mo, HR=0.9681 (95% CI 0.817, 1.147); best overall tumor 
response (all PR) P500 7.1% versus P900 4.3% (p=0.1616). As sum-
marized in the table below, the frequency of Grade 3/4 CTC toxicity 
was somewhat higher in the P900 arm. Likewise, patients on the P900 
arm were hospitalized more frequently for drug-related adverse events 
(P500: 10.7% patients; P900 arm: 15.8% patients), and required more 
blood transfusions (% patients requiring **1 transfusion: P500: 16.9%, 
P900 arm: 20.4%).
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Conclusion: Pemetrexed 900 mg/m2 did not improve survival, progres-
sion-free survival or tumor response over pemetrexed 500 mg/m2 for 
patients with platinum-pretreated advanced NSCLC patients. Certain 
toxicities and clinical sequelae were more frequent in the high dose 
group. Pemetrexed 500 mg/m2 iv q3week should be considered the 
standard dose for second-line treatment of NSCLC.
Maximum CTC Toxicity, Grade 3/4, Occurring in  
> 5% Patients in Either Arm, Regardless of Causality
P 500 N=290 P 900 N=240*
Neutropenia 3.4 7.9
Anemia 4.5 5.8
Thrombocytopenia 2.8 5.4
Fatigue 7.9 11.3
Dyspnea 5.2 5.4
Infection without neutropenia 5.2 6.3
*Safety data for the 51 pts who switched from P 900 to P 500 are not shown here.
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Background: Pemetrexed has shown activity in non-small cell lung 
cancer (NSCLC), both as single drug and in combination with plati-
nums. A prospective, randomized, multicentre study was conducted 
to compare pemetrexed + carboplatin (PC) with a standard regimen, 
gemcitabine + carboplatin (GC).
Methods: Chemonaive patients with veriﬁed NSCLC, stage IIIB (ineli-
gible for curative radiotherapy) or stage IV, WHO performance status 
(PS) 0-2, adequate hematology and calculated creatinine-clearance ≥ 
45 ml/min were eligible. All patients were supplemented with folic acid 
0.4 mg OD and vitamin B12 1 mg IM every 9 weeks, from ≥ 5 days 
before and through the treatment period. Patients were randomized to 
receive either pemetrexed 500 mg/m2 + carboplatin AUC=5 (Calvert’s 
formula) day 1 or gemcitabine 1000 mg/m2 day 1 & 8 + carboplatin 
AUC=5 (Calvert’s formula) day 1. Maximum 4 courses were given 
every 3 weeks. Primary endpoints were deﬁned as global health, nau-
sea/vomiting, dyspnea and fatigue measured by the EORTC QLQ-C30 
and LC13 before every cycle and until 11 weeks after chemotherapy. 
Secondary endpoints were overall survival (OS) and toxicity measured 
by the CTCAE v3.0. Stratiﬁcation was done for age (<75 vs ≥75 years), 
stage (IIIB vs IV) and PS (0-1 vs 2). 190 evaluable patients in each arm 
were required to detect a 15 % improvement on predeﬁned QoL param-
eters with an α of 0.05 and β of 0.80. A loss to follow up of maximum 
15 % was expected.
Results: 446 patients were enrolled from Apr 05 - Jul 06. The two arms 
were well balanced with respect to age, gender, stage, PS and histologi-
cal classiﬁcation. 423 patients were eligible for the primary QoL-analy-
sis and analyses on toxicity (patients who received ≥1 cycle of chemo-
therapy). There were no statistical signiﬁcant differences in mean score 
of the primary endpoints between the treatment arms. No difference in 
grade 3-4 anemia was observed (13 % vs. 12 %). Signiﬁcantly more 
patients in the GC arm experienced grade 3-4 thrombocytopenia (57 % 
vs. 24 %, p<.001), leucopenia (46 % vs. 22 %, p<.001) and granulocy-
topenia (51 % vs 39 %, p=.027). More patients in the GC arm received 
transfusion of platelets (9 % vs. 3 %, p=.007). No difference in the 
frequency of neutropenic fever was recorded. The ﬁnal OS analyses 
will be presented at the IASLC World Conference.
Conclusions: No differences were detected between the two arms 
with respect to the primary QoL outcome. However, patients in the PC 
arm experienced signiﬁcantly less toxicity with respect to leucopenia, 
granulocytopenia and thrombocytopenia.
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Background: Vinﬂunine is a novel microtubule inhibitor obtained by 
semi-synthesis using superacidic chemistry to selectively modify the 
catharanthine moiety of Vinca alkaloid with clinical activity in NSCLC 
(J. Bennouna, BJC, 2006). Single-agent efﬁcacy and safety of VFL and 
docetaxel (DTX) were compared in second line NSCLC. 
Methods: Open-label, multi-centre, randomised, phase III study in 
platinum pre-treated advanced/metastatic NSCLC pts. At least 275 pts 
were to be randomised by arm to receive VFL (320mg/m2, 20-min IV 
infusion) or DTX (75mg/m2, 1-hour IV infusion with dexamethasone 
over 3 days) every 3 weeks. The primary objective was to compare 
progression free survival (PFS), with a non-inferiority analysis based 
on a 10% difference (types I and II error rates: 5%, 20%), response and 
safety were assessed according RECIST and NCI CTC (version 2.0) 
respectively. Patient’s beneﬁt was also evaluated. From 06/03 to 03/05, 
551 pts were randomised (VFL: 274; DTX: 277) and 547 treated (411 
men, 136 women; median age 61 years [range 22-83]; ECOG PS 0-1: 
89%; metastatic: 90%). All pts were platinum pre-treated, in combina-
tion with a vinca alkaloid (22%), paclitaxel (21%), or gemcitabine 
(48%). A total of 950 [1-20] and 1025 [1-18] cycles were given with 
VFL and DTX respectively. Grade 3/4 toxicities: neutropenia (33% 
v 30%), anaemia (8% v 3%), thrombocytopenia (2% v <1%), febrile 
neutropenia (3% v 5%), fatigue (11% v 6%), vomiting (2% v 1%), 
abdominal pain (4% v <1%), constipation (7% v <1%) resulting in 
low toxicity in both arms. Alopecia (20% v 35%), nail disorders (1% v 
6%), injection site reaction (25% v 1%), peripheral neuropathy (11% v 
15%), diarrhoea (6% v 12%) were observed. Efﬁcacy: All efﬁcacy end-
